Clearmind Medicine Inc. (CMND) is bolstering its scientific advisory board with the appointment of Mark Haden.
The scientific advisory board’s (SAB) initial focus, said the company, will be to guide the company as it requests an Investigational New Drug review from the US Food and Drug Administration.
The request is for the company’s MEAI, a psychedelic-derived therapeutic used to treat Alcohol Use Disorder.
Mr. Haden has spent his career working to advance the use of psychedelics in medicine. He is currently the director of clinical research at Psygen Industries, a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research.
Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the appointment.
“[Mark’s] research into psychedelics and their potential to treat addiction parallels the work we are doing to develop therapies to manage AUD, and I am confident that his contribution to our efforts to secure FDA approval for MEAI will be invaluable,” he said.
Mr. Haden has dedicated over 25 years to working directly with patients through the Vancouver Coastal Health Addiction Services.
“Clearmind’s innovative approach to harnessing the properties of psychedelics to create therapeutics for mental health issues has the potential to change millions of lives around the world,” said Mr. Haden about his new role.
“I have spent my career on a similar quest, and I am delighted to facilitate this effort in any way I can.”
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems.
Clearmind Medicine Inc. (CMND) closed trading at $0.98 per share.